Table 4.
Assessment of efficacy of drug-loaded Two and Three Layer Gold Nanoparticles in 3D cell culture with three non-small cell lung cancer (NSCLC) cell lines.
| A | |||
|---|---|---|---|
| Incorporated Drug | Cell Line | Type | IC50 (μM) |
| Cisplatin | A549 | Free Drug | 26.6 ± 3.0 |
| Two Layer | 14.8 ± 0.4 | ||
| Three Layer | 15.9 ± 1.2 | ||
| H358 | Free Drug | 32.9 ± 3.4 | |
| Two Layer | 17.4 ± 0.4 | ||
| Three Layer | 10.8 ± 1.3 | ||
| PC9 | Free Drug | 16.6 ± 4.5 | |
| Two Layer | 13.4 ± 1.4 | ||
| Three Layer | 7.6 ± 2.4 | ||
| B | |||
|---|---|---|---|
| Incorporated Drug | Cell Line | Type | IC50 (nM) |
| Paclitaxel | A549 | Free Drug | 38.3 ± 4.2 |
| Two Layer | 28.5 ± 6.9 | ||
| Three Layer | 34.2 ± 2.6 | ||
| H358 | Free Drug | 45.6 ± 8.1 | |
| Two Layer | 19.0 ± 1.0 | ||
| Three Layer | 25.2 ± 3.3 | ||
| PC9 | Free Drug | 30.7 ± 4.6 | |
| Two Layer | 20.0 ± 1.6 | ||
| Three Layer | 24.4 ± 2.0 | ||